Julien Mazieres

Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial

Yi‐Long Wu, Valentina Guarneri, Pei Jye Voon et al. · The Lancet Oncology · 2024 · 70 citations · Full text

Met Amplification, Medicine, Pathology +8

Efficacy of immune-checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) patients harboring activating molecular alterations (ImmunoTarget).

Julien Mazieres, Alexander Drilon, Laurent Mhanna et al. · Journal of Clinical Oncology · 2018 · 54 citations

Immunology, Pathology, Immunotherapy +19

Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.

Arnaud Scherpereel, Julien Mazieres, Laurent Greillier et al. · Journal of Clinical Oncology · 2017 · 51 citations

Lba8507 Background, Ifct-1501 Maps2, Multimodality +17

Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial.

Arnaud Scherpereel, Julien Mazieres, Laurent Greillier et al. · Journal of Clinical Oncology · 2017 · 23 citations

Surgical Oncology, Ifct-1501 Maps2, Cancer Management +19

Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non–small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04).

Bob T. Li, Myung‐Ju Ahn, Kōichi Goto et al. · Journal of Clinical Oncology · 2022 · 20 citations

Her2-mutant Nsclc, Tps9137 Background, Medicine +15